title: Recurrent inflammatory pseudotumor of the jaw with perineural intracranial invasion demonstrating sustained response to Rituximab.
abstract: Corticosteroids are the mainstay of treatment of inflammatory pseudotumor (IPT) of the head and neck; however, involvement of the skull base and mandible can be unresponsive to steroids and require surgical resection. IPT is known to usually contain a CD20+ lymphocyte subgroup. Rituximab, a chimeric anti-CD20 antibody, has been successfully utilized in the treatment of other CD20+ diseases, including the similar idiopathic orbital inflammatory disease. This is the first report to describe successful treatment with Rituximab of a recurrent IPT of the mandible with trigeminal spread and leptomeningeal involvement with clinical and radiologic evidence demonstrating a sustained response to therapy.
authors.affiliation: Florida State University College of Medicine-Orlando Campus, 250 East Colonial Drive Suite 200, Orlando, FL 32801, USA. bag08@med.fsu.edu
authors.forename: Bryan A
authors.initials: BA
authors.lastname: Garcia
authors.forename: Sarah
authors.initials: S
authors.lastname: Tinsley
authors.forename: Thomas
authors.initials: T
authors.lastname: Schellenberger
authors.forename: George C
authors.initials: GC
authors.lastname: Bobustuc
mesh_terms: D000328:Adult; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006104:Granuloma, Plasma Cell / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008297:Male; D008336:Mandibular Diseases / Q000188:drug therapy* / Q000473:pathology; D008578:Meninges / Q000473:pathology*; D009361:Neoplasm Invasiveness; D012008:Recurrence; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab